3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
18
Kidney Neoplasms
2
Urogenital Neoplasms
1
Thrombocytopenia
1
Renal Insufficiency
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Metastatic Hormone Naive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Metastatic Castration Resistant Prostate Cancer
1
Liver Neoplasms
1
High-Risk Localized Prostate Cancer
1
Genital Neoplasms, Male
1
Cytopenia
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Anemia
1
Interventions
fluzoparib
1
enzalutamide
1
apatinib
1
Prednisone
1
Pluvicto
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Metastatic Castration Resistant Prostate Cancer
×
Pluvicto
×
Clear all
NCT03042312
2021-03-24
RESIST-PC
Endocyte
Phase 2
Terminated
71 enrolled
15 charts